The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | The potential role of CTCs as an independent prognostic factor in multiple myeloma
Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, Netherlands, discusses the potential of circulating tumor cells (CTCs) as a prognostic factor in multiple myeloma, highlighting that high CTC levels are an unfavorable prognostic factor and an independent predictor of outcome in multivariate analysis. Prof. Sonneveld notes that CTC analysis using next-generation flow is a practical tool that can provide rapid results, making it a useful aid for clinicians to identify high-risk patients who may benefit from intensified therapy. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This analysis was done post hoc in the dataset and the samples of the patients in the PERSEUS trial. I did not present it here at the IMS meeting because it has been published in Blood recently. What we know now is that the high levels of CTCs are an unfavorable prognostic factor. And in the multivariate analysis, CTCs come out as an independent prognostic factor together with molecular abnormalities and the standard prognostic factors in multiple myeloma...
This analysis was done post hoc in the dataset and the samples of the patients in the PERSEUS trial. I did not present it here at the IMS meeting because it has been published in Blood recently. What we know now is that the high levels of CTCs are an unfavorable prognostic factor. And in the multivariate analysis, CTCs come out as an independent prognostic factor together with molecular abnormalities and the standard prognostic factors in multiple myeloma. CTCs can be analyzed quite easily using next-generation flow, which is available in many hospitals, and the results will be available within one or two days. So it’s an excellent tool for clinicians to use, and it will help them to identify patients with high-risk multiple myeloma, which may in the near future also have an effect and influence on the choice of therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
